MTIF2

Across TCGA pan-cancer cohorts, MTIF2 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated MTIF2 data layer compared with 21 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher MTIF2 Mutation is associated with better overall survival. In most high-consensus cancer types, elevated MTIF2 expression acts as an unfavorable survival marker, although some lineages such as BLCA show a favorable association.

BLCA, SCLC, and SKCM are the cancer types where MTIF2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	III,IV	0.778	0.345	.017	25	view →
SCLC	OS	Median	All	0.082	0.708	<.001	12	view →
SKCM	OS	Median	All	0.210	0.781	<.001	10	view →
CESC	OS	Median	II,III,IV	0.227	0.759	.029	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
LIHC	DFS	Median	II,III,IV	0.044	0.427	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

MTIF2–BLCA (OS)

Open the BLCA breakdown →